Fact-Checkers Find Few Flaws in Clinton's Healthcare Claims

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: The Hill, Sam Baker (9/6/12)

"Self-proclaimed fact-checkers have drawn plenty of criticism from both parties, as well as neutral observers, and many individual assessments of 'fact' are highly debatable. In the aggregate, though, the fact-checkers haven't found much to complain about in Clinton's healthcare comments."

The Hill, Sam Baker

Bill Clinton's long, detailed arguments on healthcare are mostly holding up under scrutiny from the cottage industry of political fact-checkers.

Healthcare was a big part of Clinton's policy-laden speech Wednesday night at the Democratic convention in Charlotte, N.C. He defended President Obama's healthcare law, including its controversial Medicare savings, and took a hard swipe at Republicans' proposals for Medicaid.

Self-proclaimed fact-checkers have drawn plenty of criticism from both parties, as well as neutral observers, and many individual assessments of "fact" are highly debatable. In the aggregate, though, the fact-checkers haven't found much to complain about in Clinton's healthcare comments.

The biggest criticism centers around Clinton's claim that healthcare costs aren't rising as quickly as they did in the past. . .View Full Article

Two Firms Aim To Create Functional Cure for Type 1 Diabetes
Source: Streetwise Reports (11/22/2024)

Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs.

Biotech Initiates Phase III Trial for Heart Disease Drug
Source: Streetwise Reports (11/20/2024)

Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock.

Analyst Says Biotech's Data Supports Advancement Into Phase III
Source: Dr. Douglas Loe (11/19/2024)

Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.

Safe Supply Streaming Co. Ltd (SPLY:CSE; SSPLF:OTCQB; QM4:FSE) recently announced significant developments within its portfolio company, Safety Strips, and a key acquisition. Learn more about how these strategic developments aim to enhance harm reduction efforts and expand market reach.